To evaluate the correlation between LivQ-box® parameters carried by iLivTouch and liver inflammation in patients with NAFLD, as well as the diagnostic value of liver inflammation of different severity levels.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients diagnosed with NAFLD according to The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases;
* Age over 18 years old, gender not limited;
* Not combined with liver diseases (such as viral hepatitis, drug-induced liver injury, autoimmune liver disease);
* Perform iLivTouch examination within ± 14 days of liver pathology examination;
* No history of excessive alcohol consumption (converted to ethanol:\<140g/week for males,\<70g/week for females);
Primary outcome measure(s)
Evaluate the correlation and diagnostic performance of LivQ-box and cut-off values for different inflammation stages in NAFLD patients based on iLivTouch. — 12 months
Trial sites (1)
Facility
City
Region
Status
Beijing Tsinghua Changgung Hospital (BTCH) affiliated to Tsinghua University
Beijing
Beijing Municipality
Recruiting
More Wuxi Hisky Medical Technology Co Ltd trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.